PCA
RXRX icon

Private Capital Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Private Capital Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,685
Closed -$120K – 90
2023
Q3 		$120K Buy
+22,685
New +$226K 0.02% 87

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Private Capital Advisors's RXRX Position: Q4 2023 in Review

Private Capital Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 22,685 shares — an estimated $120K sold.

Private Capital Advisors first reported a position in RXRX in Q3 2023 and held it in 1 quarter. The position peaked at $120K in Q3 2023. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

  • Private Capital Advisors reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Private Capital Advisors sold 22,685 Recursion Pharmaceuticals shares in Q4 2023, an estimated $120K.
  • Private Capital Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Private Capital Advisors's Recursion Pharmaceuticals position peaked at $120K in Q3 2023.
  • 199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Private Capital Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.